CE: Sodium-Glucose Co-transporter 2 Inhibitors: Safety Considerations and Clinical Implications for Healthcare Providers

Gyen Musgrave

Abstract


Sodium-Glucose Co-transporter-2 inhibitors have been adopted into the most recent American Diabetes Association Guidelines as a now integral part of diabetes care. These medications may be involved in effective strategies to lower glycosylated hemoglobin (A1C), blood glucose, long-term neuropathies and other diabetic complications. Specifically, these drugs have recently been accepted as the drugs of choice in diabetes care for those with cardiovascular comorbidities. Additionally, recent updates regarding Black Box Warnings with canagliflozin have stated it may cause long term increases in the overall number of amputations.  Knowledge concerning the new guidelines and the clinical implications with this class of drugs is essential to providing patient care and optimizing outcomes for patients suffering from type two diabetes mellitus.


Full Text:

PDF

Refbacks

  • There are currently no refbacks.


Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.